Get to know our clinical trials
Clinical trial LNP023 in patients with primary IgA nephropathy
THE PURPOSE OF THE STUDY IS TO FIND OUT WHETHER LNP023 IS SAFE AND EFFECTIVE IN PEOPLE WITH PRIMARY IGA NEPHROPATHY
Status
In recruitment
headquarters
Pamplona
Technical Summary
- PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PATIENTS WITH PRIMARY IGA NEPHROPATHY
- Code EudraCT: 2020-001049-38
- Protocol number: CLNP023A2301
- Promoter: Novartis Farmaceutica
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.